A human monoclonal antibody specific for TSLP, known as tezepelumab (Tezspire), was approved by the US Food and Drug Administration in 2021 as an add‐on maintenance treatment for patients aged ≥12 years with severe, uncontrolled asthma. This evidence concerns the gene TSLP and asthma.